Trans-bronchial forceps biopsy for COVID-19 related diffuse parenchymal lung abnormalities

Abstract Purpose The role of lung biopsy for evaluation of persistent chest radiographic abnormalities including secondary organizing pneumonia (OP) in COVID-19 remains uncertain. This study aimed to evaluate the diagnostic value of trans-bronchial forceps biopsy (TBFB) in patients with persistent l...

Full description

Saved in:
Bibliographic Details
Main Authors: Janina Kleymann, Sascha Brückmann, Simona Langner, Dirk Koschel, Martin Kolditz
Format: Article
Language:English
Published: BMC 2024-12-01
Series:BMC Pulmonary Medicine
Subjects:
Online Access:https://doi.org/10.1186/s12890-024-03449-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850034995884720128
author Janina Kleymann
Sascha Brückmann
Simona Langner
Dirk Koschel
Martin Kolditz
author_facet Janina Kleymann
Sascha Brückmann
Simona Langner
Dirk Koschel
Martin Kolditz
author_sort Janina Kleymann
collection DOAJ
description Abstract Purpose The role of lung biopsy for evaluation of persistent chest radiographic abnormalities including secondary organizing pneumonia (OP) in COVID-19 remains uncertain. This study aimed to evaluate the diagnostic value of trans-bronchial forceps biopsy (TBFB) in patients with persistent lung abnormalities on thoracic computed tomography (CT) scan following SARS-CoV-2 infection with particular focus on cases with OP and immunocompromised (IC) patients. Methods Descriptive retrospective single center analysis of all TBFB performed for diffuse lung parenchymal changes after COVID-19 03–2020 to 06–2023. Results Twenty seven consecutive TBFB including 23 in IC patients resulted in 100% samples with alveolar tissue showing a high frequency of 12/27 (44%) histological pattern of OP. Steroids were used in 21/27 patients (78%) including 11/12 (92%) with OP. Clinical outcome at discharge was favorable in 89% (92% with OP). Conclusion TBFB contributes to the diagnosis of diffuse parenchymal lung abnormalities in the context of COVID-19 including a frequent OP pattern particularly in IC patients. Larger studies are necessary to confirm our data and elucidate on the optimal steroid treatment modality. Trial registration Clinical trial number: not applicable. The study was approved by the Ethics Committee of the University Medicine Carl Gustav Carus, TU Dresden (BO-EK-309072023). Waiver of informed consent was granted because of the retrospective nature of the study.
format Article
id doaj-art-f4a7f7a8372f4e45907612543b22017e
institution DOAJ
issn 1471-2466
language English
publishDate 2024-12-01
publisher BMC
record_format Article
series BMC Pulmonary Medicine
spelling doaj-art-f4a7f7a8372f4e45907612543b22017e2025-08-20T02:57:39ZengBMCBMC Pulmonary Medicine1471-24662024-12-012411810.1186/s12890-024-03449-0Trans-bronchial forceps biopsy for COVID-19 related diffuse parenchymal lung abnormalitiesJanina Kleymann0Sascha Brückmann1Simona Langner2Dirk Koschel3Martin Kolditz4Medical Department I, Division of Pneumology, University Hospital Carl Gustav Carus, TU DresdenInstitute of Pathology and Tumor- and Normal Tissue Bank of the University Cancer Center (UCC), University Hospital Carl Gustav Carus, Medical Faculty, Technische Universität DresdenMedical Department I, Division of Pneumology, University Hospital Carl Gustav Carus, TU DresdenMedical Department I, Division of Pneumology, University Hospital Carl Gustav Carus, TU DresdenMedical Department I, Division of Pneumology, University Hospital Carl Gustav Carus, TU DresdenAbstract Purpose The role of lung biopsy for evaluation of persistent chest radiographic abnormalities including secondary organizing pneumonia (OP) in COVID-19 remains uncertain. This study aimed to evaluate the diagnostic value of trans-bronchial forceps biopsy (TBFB) in patients with persistent lung abnormalities on thoracic computed tomography (CT) scan following SARS-CoV-2 infection with particular focus on cases with OP and immunocompromised (IC) patients. Methods Descriptive retrospective single center analysis of all TBFB performed for diffuse lung parenchymal changes after COVID-19 03–2020 to 06–2023. Results Twenty seven consecutive TBFB including 23 in IC patients resulted in 100% samples with alveolar tissue showing a high frequency of 12/27 (44%) histological pattern of OP. Steroids were used in 21/27 patients (78%) including 11/12 (92%) with OP. Clinical outcome at discharge was favorable in 89% (92% with OP). Conclusion TBFB contributes to the diagnosis of diffuse parenchymal lung abnormalities in the context of COVID-19 including a frequent OP pattern particularly in IC patients. Larger studies are necessary to confirm our data and elucidate on the optimal steroid treatment modality. Trial registration Clinical trial number: not applicable. The study was approved by the Ethics Committee of the University Medicine Carl Gustav Carus, TU Dresden (BO-EK-309072023). Waiver of informed consent was granted because of the retrospective nature of the study.https://doi.org/10.1186/s12890-024-03449-0Trans-bronchial biopsyCOVID-19 related lung changesOrganizing PneumoniaImmunocompromised
spellingShingle Janina Kleymann
Sascha Brückmann
Simona Langner
Dirk Koschel
Martin Kolditz
Trans-bronchial forceps biopsy for COVID-19 related diffuse parenchymal lung abnormalities
BMC Pulmonary Medicine
Trans-bronchial biopsy
COVID-19 related lung changes
Organizing Pneumonia
Immunocompromised
title Trans-bronchial forceps biopsy for COVID-19 related diffuse parenchymal lung abnormalities
title_full Trans-bronchial forceps biopsy for COVID-19 related diffuse parenchymal lung abnormalities
title_fullStr Trans-bronchial forceps biopsy for COVID-19 related diffuse parenchymal lung abnormalities
title_full_unstemmed Trans-bronchial forceps biopsy for COVID-19 related diffuse parenchymal lung abnormalities
title_short Trans-bronchial forceps biopsy for COVID-19 related diffuse parenchymal lung abnormalities
title_sort trans bronchial forceps biopsy for covid 19 related diffuse parenchymal lung abnormalities
topic Trans-bronchial biopsy
COVID-19 related lung changes
Organizing Pneumonia
Immunocompromised
url https://doi.org/10.1186/s12890-024-03449-0
work_keys_str_mv AT janinakleymann transbronchialforcepsbiopsyforcovid19relateddiffuseparenchymallungabnormalities
AT saschabruckmann transbronchialforcepsbiopsyforcovid19relateddiffuseparenchymallungabnormalities
AT simonalangner transbronchialforcepsbiopsyforcovid19relateddiffuseparenchymallungabnormalities
AT dirkkoschel transbronchialforcepsbiopsyforcovid19relateddiffuseparenchymallungabnormalities
AT martinkolditz transbronchialforcepsbiopsyforcovid19relateddiffuseparenchymallungabnormalities